Nuvalent Inc Ordinary Shares - Class A NUVL 深 滬
等待開盤 09-20 09:30:00 美东时间
103.25
+0.620
+0.60%
華盛通- 最 高107.98
- 今 開104.87
- 成交量 98.25万股
- 最 低 102.62
- 昨 收 102.63
- 總市值 72.07亿
- 52周最高 113.51
- 市盈率 靜 --
- 換手率 1.41%
- 52周最低 41.16
- 委 比 69.49%
- 總股本 6979.76万
- 歷史最高 113.51
- 量 比 0.72
- 振 幅 5.22%
- 歷史最低 7.09
- 每 手 1
- 風險率 11.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Nuvalent (NUVL) Shares Are Down 6% Today
Nuvalent shares are trading lower by 6.2% during Tuesday's session. The company priced a $500 million public offering of 5 million shares at $100 each.
09-18 02:37
Nuvalent announces pricing of $500M upsized stock offering
Nuvalent (NASDAQ:NUVL) has announced the pricing of an upsized underwritten public offering of 5 million shares of Class A common stock at $100.00 a share, for an expected gross proceeds to be approxi...
09-17 13:37
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
CAMBRIDGE, Mass., Sept. 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL),...
09-17 10:23
Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity
Nuvalent presented updated Phase 1 data from its ARROS-1 and ALKOVE-1 trials at the ESMO Congress 2024. Key data showed promising response rates in pretreated patients, with pivotal results expected in 2025.
09-17 01:44
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite fall...
09-17 00:31
Nuvalent jumps 19% on $350M equity offering
Clinical-stage biopharmaceutical company Nuvalent (NASDAQ:NUVL) commenced an underwritten public offering of $350M shares. There can be no assurance as to whether or when the offering may be completed...
09-16 19:22
Nuvalent Publishes Cancer Discovery Detailing Design And Characterization Of ALK-Selective Inhibitor NVL-655
Publication provides comprehensive assessment of NVL-655's preclinical activity and includes preliminary clinical case studies
09-13 22:00
Nuvalent (NUVL) Receives a Buy from Barclays
Nuvalent (NUVL – Research Report) received a Buy rating and a $100.00 price tar...
08-29 16:07
Nuvalent Begins Phase 1 Trial for New HER2-Selective Lung Cancer Treatment
Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the
07-22 18:31
Nuvalent names Henry Pelish as chief scientific officer
Nuvalent (NASDAQ:NUVL) said Henry Pelish has been promoted to chief scientific officer. Pelish had played a vital role in the creation of Nuvalent and had joined as biology lead in 2018. More on Nuval...
07-11 18:45
